¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16
±³À°ÀÏÀÚ : 2018-11-16
±³À°Àå¼Ò : °­¸ª¾¾¸¶Å©È£ÅÚ ¾Æ»êÆ®¸®¿ò  
±³À°ÁÖÁ¦ : Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  
À̸ÞÀÏ : webmaster@rheum.or.kr      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : °­¿øµµ
±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 60,000¿ø      
ºñ°í : ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 80,000¿øȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 40,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 80,000¿ø, ÇöÀåµî·Ï 100,000¿øºñȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:00~09:30 Validation of FRAX for osteoporosis treatment decision in patients with osteoarthritis: A multicenter comparative study of FRAX criteria and WHO criteria  ±èº¸¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:30~10:00 Angiogenesis using smart material  ±è¼º°ï(°­¸ª¿øÁÖ´ë Ä¡´ë ±¸°­¾Ç¾È¸é¿Ü°úÇÐ) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 10:00~10:30 Ãµ¿¬¹°À» ÀÌ¿ëÇÑ °ñ´Ù°øÁõ Ä¡·áÁ¦ °³¹ß  À¯ÁöÇý(KIST) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:00~11:40 Systemic and local fat in knee osteoarthritis.  Changhai Ding(Univ. of Tasmania, Australia) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:20~12:00 Management of systemic sclerosis -current status and future directions  Masataka Kuwana(Nippon Medical School, Japan) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 12:10~12:40 ICHOM standard set of outcomes that matter to patients suffering from inflammatory arthritis, explaining the goal of ICHOM, the methodology and how to apply this global development Mart  A.F.J van de Laar(University of Twente, the Netherlands) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:30~13:50 What¡¯s the choice after failure of first anti-TNF in RA?  Â÷ÈƼ®(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:50~14:10 To taper or not to taper biologics in RA?  ½É½Âö(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:10~14:30 Can we stop progression of structural damage in axial SpA?  ±è¿ë±æ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:30~14:50 Do we need to supplement vitamin D in autoimmune rheumatic diseases?  ±è±ÙÅÂ(°í½ÅÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:30~15:50 New therapy in SLE: is the glass half-full or half-empty?  ¼­Ã¢Èñ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:50~16:10 Can we withdraw Immunosuppressants in patients with lupus nephritis in remission?  ¼ºÀ±°æ(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:10~16:30 Do we still need biopsy to diagnose Sjögren¡¯s syndrome?  °û½Â±â(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:30~16:50 How can we better manage interstitial lung disease in systemic sclerosis?  ÀÌÀººÀ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:00~09:30 ÀÓ»óÁø·áÁöħ °³¹ß °³¿ä¿Í ±âȹ  ±èÀç±Ô(Áß¾ÓÀÇ´ë, ´ëÇÑÀÇÇÐȸ Á¤Ã¥ÀÌ»ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:30~09:50 Áø·áÁöħ °³¹ß °æÇè-GIOP¿Í ¿¹¹æÁ¢Á¾À» Áß½ÉÀ¸·Î  ÀüÂùÈ«(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:50~10:05 Áø·áÁöħ °³¹ß Çʿ伺-·ù¸¶Æ¼½º °üÀý¿°  ÀÌÁö¼ö(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 10:05~10:20 Ã༺ôÃß°üÀý¿°-°­Á÷ôÃß¿° Ä¡·á±Ç°í °³¹ß  ¹éÇÑÁÖ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 13:30~14:00 Is it possible to prevent RA?  ÀÌ»óÀÏ(°æ»óÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:00~14:30 The cellular and molecular mechanisms in cartilage degeneration  Çѽ¿ì(°æºÏÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:30~15:00 CAR-T cells beyond cancer: A new therapy for autoimmune diseases?  Á¤ÁØÈ£(¼­¿ïÀÇ´ë »ýÈ­Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 15:30~16:00 Epigenetic control of immune cells.  ±è¶ô±Õ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í°úÇкÎ) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:00~16:30 Follicular helper T cell.  ÃÖÀ±¼ö(¼­¿ïÀÇ´ë ÀÇ°úÇаú) 
±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:30~17:00 Chronic/persistent infection and autoimmune diseases  ÃÖ¿µ´Ô(¼­¿ïÄ¡Àü¿ø ±¸°­¹Ì»ý¹°Çб³½Ç) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:30~13:50 ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌâÈÆ(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:50~14:10 °­Á÷ôÃß¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤.  ÀÌ»ó¿ø(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:10~14:30 °í½ÄÀû ÇÕ¼º Ç×·ù¸¶Æ¼½ºÁ¦Á¦(csDMARDs) ¾Ë¾Æº¸±â  ±èÇö¼÷(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:30~14:50 ·ù¸¶Æ¼½º ÁúȯÀÇ Ç¥ÀûÄ¡·áÁ¦.  È«½ÂÀç(°æÈñÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 4Â÷»ê¾÷Çõ¸í°ú ³ëÈ­¿¬±¸ÀÇ ¹Ì·¡ (ÀüºÏÀÇ´ë »ýÈ­Çб³½Ç ±èÁ¾¼® ±³¼ö) / °¨¼ºÀ¸·Î ½Î¿ö¶ó -º´¿ø°æ¿µ(¹éâÈñ) : 2018-11-17
´ÙÀ½±Û Ãæ³²´ëÇб³º´¿ø ´ëÀüÁö¿ª¾Ï¼¾ÅÍ È¯ÀÚ¿ì¼±ÀÇ °íÇ°°Ý ¾ÏÁø·á ½ÉÆ÷Áö¾ö : ´ÙÇÐÁ¦ ÅëÇÕÁø·á : 2018-11-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21152 ºÎ»ê ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ ¿µ³²Áöȸ ÇÏ°èÁý´ãȸ : 2024-07-11 0 2 2024-07-01
21151 ºÎ»ê ´ëÇѺñ´¢ÀÇÇÐȸ 311ȸ Çмú´ëȸ(Àü¸³¼± ¾Ï) : 2024-07-11 0 4 2024-07-01
21150 ºÎ»ê ´ëÇÑ°£ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Áý´ãȸ : 2024-07-11 0 4 2024-07-01
21149 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ (¿Â¶óÀÎ) KSMO 7¿ù ºÐ±âÁý´ãȸ : 2024-07-11 0 1 2024-07-01
21148 ÀÎõ Çѱ¹¿©ÀÚÀÇ»çȸ ÀÎõÁöȸ 7¿ù Çмú½ÉÆ÷Áö¾ö(Ä¡¸Å) : 2024-07-10 0 2 2024-07-01
21147 ¼­¿ï Á¦137ȸ ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ Áý´ãȸ : 2024-07-10 0 9 2024-07-01
21146 ¿ï»ê ¿ï»ê À̺ñÀÎÈÄ°ú Çмú ¼¼¹Ì³ª : 2024-07-09 0 3 2024-07-01
21145 ´ëÀü ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ ´ëÀüÃæûÁöȸ 7¿ù ¿¬¼ö°­Á : 2024-07-09 0 2 2024-07-01
21144 ¼­¿ï 2024 ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ Á¦33Â÷ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-07-07 0 2 2024-07-01
21143 ´ëÀü 2024 ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ´ëÀüÃæûÁöȸ ¿¬¼ö°­Á : 2024-07-07 0 4 2024-07-01
21142 ¼­¿ï 2024³â Á¦11ȸ ´ëÇѳ²¼º°úÇÐȸ-´ëÇѺñ´¢ÀÇÇаúÀÇ»çȸ °øµ¿½ÉÆ÷Áö¾ö : 2024-07-07 0 1 2024-07-01
21141 ¿ï»ê ¿ï»ê´ëÇб³º´¿ø ½Å°æ¿Ü°ú ½ÉÆ÷Áö¿ò : 2024-07-06 0 3 2024-07-01
21140 ´ë±¸ Á¦7ȸ °æºÏ´ëÇб³ ¾È°úÇб³½Ç ½ÉÆ÷Áö¾ö : 2024-07-06 0 2 2024-07-01
21139 ¼­¿ï 2024 ´ëÇѵΰæºÎ¿Ü°úÇÐȸ ÃÊÀ½ÆÄ ¿öÅ©¼ó : 2024-07-06 0 2 2024-07-01
21138 ±¤ÁÖ 2024 Àü³²´ëÇб³º´¿ø Á¤½Å°Ç°­ÀÇÇаú ±¹Á¦½ÉÆ÷Áö¾ö : 2024-07-05 0 1 2024-07-01
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷